- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05050799
US Post-Market Surveillance Study of the Surfacer System
February 7, 2024 updated by: Merit Medical Systems, Inc.
US Post-Market Surveillance Study of the Surfacer* Inside-Out* Access Catheter System (Surfacer System)
Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study.
Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.
Study Overview
Detailed Description
Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study.
A minimum of 30 patients will be enrolled in the study, all cases to be performed un-proctored at up to 12 sites in the United States, with no site enrolling more than 6 subjects.
All patients enrolled will sign an informed consent form for use of their data.
Investigators will invite patients who will be treated with the device in accordance with the approved labeling and who met enrollment criteria to join the study.
Study Type
Observational
Enrollment (Estimated)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Casey Holland, MS
- Phone Number: 6178420251
- Email: casey.holland@merit.com
Study Contact Backup
- Name: Hannah L Bergh, BS
- Phone Number: 9787586166
- Email: Hannah.bergh@merit.com
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85704
- Completed
- PIMA Heart and Vascular
-
-
Florida
-
Sarasota, Florida, United States, 34239
- Recruiting
- Sarasota Memorial Health Care System
-
Contact:
- Jason Wagner, MD
- Phone Number: 941-917-2225
- Email: jwagner@veinsandarteries.com
-
-
Texas
-
Dallas, Texas, United States, 75226
- Recruiting
- Baylor Scott & White Heart and Vascular Hospital
-
Contact:
- Javier Vasquez, MD
- Phone Number: 214-820-1722
- Email: Javier.Vasquez@BSWHealth.org
-
Pasadena, Texas, United States, 77504
- Completed
- Flow Vascular Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods and who meet requirements in the labeling of the IFU.
Description
Inclusion Criteria:
- Subjects have been referred for placement of central venous access, i.e., placement of catheter, nutritional line, etc.
- Subjects with upper body venous occlusions or other conditions that preclude central venous access by conventional methods
- Subjects are willing and able to give written informed consent
Exclusion Criteria:
- Occlusion of the right femoral vein, right iliac vein or inferior vena cava
- Acute thrombus within any vessel to be crossed by Surfacer System (SVC, jugular, IVC, brachiocephalic and subclavian)
- Occlusion within the arterial system
- Occlusion within the coronary or cerebral vasculature
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events through 24 hours
Time Frame: 24 hours
|
no procedural adverse events or peri procedural adverse events
|
24 hours
|
Central Venous Access operational
Time Frame: 24 hours
|
safe insertion of the device to facilitate central venous access
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Laura Minarsch, BS, Clinical Affairs Director
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 8, 2022
Primary Completion (Estimated)
August 10, 2024
Study Completion (Estimated)
August 31, 2024
Study Registration Dates
First Submitted
September 10, 2021
First Submitted That Met QC Criteria
September 20, 2021
First Posted (Actual)
September 21, 2021
Study Record Updates
Last Update Posted (Actual)
February 9, 2024
Last Update Submitted That Met QC Criteria
February 7, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- CVO-P4-23-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Disease
-
University Hospital, AngersCompleted
-
Neuromed IRCCSPrincipal investigator: Giacomo Frati; Co-investigator: Francesco PompeoActive, not recruiting
-
The University of Texas Health Science Center,...Terminated
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States, Australia, Germany, Italy, United Kingdom, New Zealand, Ireland
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States
-
Value Outcomes Ltd.Alfasigma S.p.A.RecruitingChronic Venous Disease | Chronic Insufficiency VenousCzechia
-
Imperial College LondonCompletedVenous Insufficiency | Chronic Venous Disease | Deep Venous ObstructionUnited Kingdom
-
Hao LiuCompletedChronic Venous Disease (CVD), Vein Compliance, Venous Clinical Severity Score (VCSS)China
-
Bokhua Memorial Cardiovascular CenterChapidze Emergency Cardiology CenterNot yet recruitingChronic Venous Disease
-
Hanlim Pharm. Co., Ltd.RecruitingChronic Venous DiseaseKorea, Republic of
Clinical Trials on Central Venous Access
-
E-DA HospitalUnknownTime to Insertion | Rates of ComplicationsTaiwan
-
Deutsche Interdisziplinäre Vereinigung für Intensiv-...Not yet recruitingCentral Venous CatheterGermany
-
Merit Medical Systems, Inc.Meditrial Europe Ltd.CompletedVenous OcclusionUnited States
-
Pakistan Navy Station Shifa HospitalCompletedCentral Venous Pressure | Peripherial Venous Pressure | Fluid/Volume Status Monitoring of PatientPakistan
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
University Hospital of PatrasCompletedPacemaker | Implantable Cardioverter-defibrillatorGreece
-
General Hospital GroeningeCompletedOncology | Haematological MalignancyBelgium
-
University Hospital of FerraraCompletedArrhythmias, Cardiac | Implantable Defibrillator User | Vascular Access Complication | Venous Puncture | Pacemaker Complication | Fluoroscopy; Adverse EffectItaly
-
University of Colorado, DenverChildren's Hospital ColoradoRecruitingCentral Venous Catheter Related Bloodstream Infection | Central Venous Catheter Exit Site InfectionUnited States
-
Hospices Civils de LyonCompletedVascular Access ComplicationFrance